Scilex Holding Reports Preliminary Q3 2024 Net Sales Of ZTlido In Range Of $11M-$13M, Up 9%-29% YoY; Total Product Net Sales Estimated At $12M-$14M, Up 19%-39% YoY
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company reported preliminary Q3 2024 net sales for ZTlido in the range of $11M-$13M, showing a 9%-29% year-over-year increase. Total product net sales are estimated at $12M-$14M, reflecting a 19%-39% growth compared to the same period last year.
October 08, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex Holding Company reported strong preliminary Q3 2024 sales growth for its ZTlido product, with net sales increasing by 9%-29% year-over-year. Total product sales also showed significant growth of 19%-39%, indicating robust demand for its non-opioid pain management solutions.
The reported sales growth for ZTlido and total products indicates strong market performance and demand for Scilex's offerings. This positive financial result is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100